Table 4.
Subgroup analysis of association between internal malignancy and actinic keratosis by sex and age.
| Cancer | Sex | Age (years) | |||
|---|---|---|---|---|---|
| Male | Female | 20–39 | 40–64 | ≥ 65 | |
| Adjusted HR (95% CI)* | Adjusted HR (95% CI)* | Adjusted HR (95% CI)* | Adjusted HR (95% CI)* | Adjusted HR (95% CI)* | |
| Overall cancer | 1.25 (1.19, 1.32) | 1.61 (1.54, 1.68) | 1.30 (1.04, 1.62) | 1.18 (1.10, 1.27) | 1.52 (1.46, 1.58) |
| Skin cancer | 2.12 (1.22, 3.69) | 4.59 (3.03, 6.94) | – | 2.08 (0.91, 4.76) | 3.85 (2.69, 5.51) |
| Oral cavity and pharyngeal cancer | 1.81 (1.33, 2.47) | 2.30 (1.59, 3.33) | – | 2.22 (1.46, 3.39) | 1.92 (1.44, 2.55) |
| Lymphoma | 1.81 (1.33, 2.47) | 1.43 (1.06, 1.94) | 0.77 (0.18, 3.43) | 1.30 (0.85, 2.01) | 1.76 (1.37, 2.28) |
| Leukemia | 1.38 (0.96, 1.99) | 1.34 (0.90, 1.98) | 1.48 (0.31, 7.13) | 1.28 (0.73, 2.25) | 1.37 (1.01, 1.87) |
| Prostate cancer | 1.35 (1.21, 1.51) | – | – | 1.16 (0.89, 1.50) | 1.41 (1.25, 1.59) |
| Renal cancer | 1.41 (1.05, 1.88) | 1.12 (0.76, 1.64) | 1.58 (0.52, 4.85) | 1.22 (0.81, 1.83) | 1.31 (0.98, 1.75) |
| Multiple myeloma | 0.58 (0.30, 1.12) | 0.69 (0.41, 1.17) | – | 0.31 (0.10, 0.98) | 0.76 (0.49, 1.18) |
| Liver cancer | 1.00 (0.86, 1.16) | 1.53 (1.31, 1.78) | 0.95 (0.28, 3.27) | 0.99 (0.79, 1.23) | 1.30 (1.15, 1.47) |
| Thyroid cancer | 1.54 (1.14, 2.08) | 1.13 (0.97, 1.32) | 1.37 (0.98, 1.93) | 1.16 (0.97, 1.39) | 1.20 (0.94, 1.55) |
| Laryngeal cancer | 1.11 (0.72, 1.73) | 1.51 (0.41, 5.48) | – | 1.08 (0.45, 2.62) | 1.17 (0.73, 1.88) |
| Esophageal cancer | 1.06 (0.75, 1.50) | 1.49 (0.74, 3.03) | – | 0.83 (0.41, 1.69) | 1.23 (0.87, 1.73) |
| Gastric cancer | 0.98 (0.86, 1.11) | 1.33 (1.17, 1.52) | 2.41 (1.14, 5.12) | 1.12 (0.93, 1.34) | 1.12 (1.00, 1.24) |
| Colorectal cancer | 0.99 (0.88, 1.12) | 1.06 (0.95, 1.19) | 1.52 (0.77, 2.99) | 0.97 (0.81, 1.15) | 1.04 (0.94, 1.14) |
| Pancreatic cancer | 1.10 (0.88, 1.27) | 1.25 (1.06, 1.47) | 2.24 (0.78, 6.44) | 1.19 (0.92, 1.55) | 1.14 (0.99, 1.31) |
| Biliary cancer | 0.97 (0.75, 1.26) | 0.92 (0.74, 1.15) | – | 0.79 (0.50, 1.26) | 0.96 (0.81, 1.16) |
| Lung cancer | 0.99 (0.88, 1.11) | 1.21 (1.04, 1.40) | – | 1.09 (0.88, 1.34) | 1.06 (0.95, 1.18) |
| Bladder cancer | 1.17 (0.96, 1.44) | 1.15 (0.81, 1.63) | – | 1.17 (0.78, 1.77) | 1.17 (0.96, 1.43) |
| Cancer of central nervous system | 1.01 (0.67, 1.50) | 1.6 (1.13, 2.27) | 0.42 (0.05, 3.19) | 1.61 (0.96, 2.69) | 1.25 (0.92, 1.71) |
| Breast cancer | 1.71 (0.35, 8.50) | 1.08 (0.92, 1.26) | 1.25 (0.72, 2.16) | 0.99 (0.79, 1.25) | 1.15 (0.91, 1.46) |
| Uterine cervical cancer | – | 1.02 (0.75, 1.37) | 0.87 (0.30, 2.51) | 0.82 (0.47, 1.44) | 1.15 (0.79, 1.69) |
| Uterine corpus cancer | – | 1.21 (0.85, 1.74) | 1.88 (0.59, 6.02) | 1.02 (0.56, 1.85) | 1.27 (0.78, 2.06) |
| Ovarian cancer | – | 1.08 (0.82, 1.42) | 1.17 (0.44, 3.10) | 1.16 (0.70, 1.91) | 1.03 (0.72, 1.47) |
| Testicular cancer | 0.86 (0.33, 2.21) | – | – | – | 0.96 (0.37, 2.50) |
*Adjustment for diabetes mellitus, hypertension, dyslipidemia, habitat, and income status.